凯赛生物: 2025年第二次临时股东大会法律意见书

Core Viewpoint - The legal opinion letter from Shanghai Jintiancheng Law Firm confirms the legality of the procedures and qualifications for the 2025 Second Extraordinary General Meeting of Shanghai Kaisa Biotechnology Co., Ltd. [1][6] Group 1: Meeting Procedures - The meeting was proposed and convened by the board of directors, with the notice published on August 2, 2025 [3][4]. - The meeting combined on-site and online voting, held on August 18, 2025, at a specified location [4][6]. - The legal opinion confirms that the convening and holding procedures comply with relevant laws and regulations [6]. Group 2: Attendance and Qualifications - A total of 171 shareholders and representatives attended the meeting, representing 517,786,578 shares, which is 72.02% of the total voting shares [5]. - The legal opinion verifies that all attendees had valid qualifications according to applicable laws and the company's articles of association [5][6]. Group 3: Proposals and Voting Results - The meeting included proposals for amendments to various internal rules and the election of new board members [7][8]. - Voting results showed that all proposals were approved, with significant support from shareholders [12]. - Specific voting results indicated that the proposals received over 515 million votes in favor, demonstrating strong shareholder backing [8][12].